The expression of programmed death receptor ligand 1 (PD-L1) in tumor tissues is a widely used criterion for choosing immunotherapy regimens, yet its predictive value for esophageal cancer outcomes is still debatable. The gene discussed is CD274; the disease is neoplasm.